ReviewFrontiers in immunology2023
Diversity of immune checkpoints in cancer immunotherapy.
Review in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 62 citations in OpenAlex.
- Recent advances in the regulation of CD47 by non-coding RNAs and its therapeutic potential in cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Soluble Immune Checkpoints as Prognostic Biomarkers in Small Cell Lung Cancer Patients Treated with Chemotherapy and Anti-PD-L1.International journal of molecular sciences · 2026Article
- Peptide-mediated immunomodulation of tumor microenvironment in triple-negative breast cancer: A comprehensive review.The Journal of pharmacology and experimental therapeutics · 2026Review
- Evolving Landscape of Glioblastoma Research: Integrating Therapeutic Advances and Diagnostic Frontiers.Brain sciences · 2026Review
- Pan-Cancer Analysis of ANO6 and Experimental Validation in Metastatic Melanoma.Biochemical genetics · 2026Article
- Mechanisms and intervention strategies of microenvironment-mediated drug resistance in multiple myeloma.Cancer cell international · 2026Review
- Current Insights into the Role of Peripheral Blood Immune Cell Phenotypes in Resistance to Cancer Therapies.Oncology research · 2026Review
- Regulation of immune checkpoints by electronic cigarette.Frontiers in oncology · 2026Review
- Immune checkpoint blocking in cancer therapy using thermosensitive hydrogels: a review.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Emerging roles of KIR2DL4 in cancer immunotherapy.Breast cancer (Tokyo, Japan) · 2025Review
- Article
- Leveraging the Tumor Microenvironment as a Target for Cancer Therapeutics: A Review of Emerging Opportunities.Pharmaceutics · 2025Review
- [The role of immunosurveillance and immunoediting in hereditary cancer predisposition syndromes].Magyar onkologia · 2025Review
- Precision medicine in gynecological cancer (Review).Biomedical reports · 2025Review
- Cancer Vaccines and Beyond: The Transformative Role of Nanotechnology in Immunotherapy.Pharmaceutics · 2025Review
- Advances in the understanding and therapeutic manipulation of cancer immune responsiveness: a Society for Immunotherapy of Cancer (SITC) review.Journal for immunotherapy of cancer · 2025Review
- Flow Cytometric Profiling of Peripheral Immune Checkpoints Predicts Prognosis and Reveals PD-1/Treg/IL-10 Crosstalk in B-Cell Lymphoma.ImmunoTargets and therapy · 2025Article
- Natural Killer Cell Immune Checkpoints and Their Therapeutic Targeting in Cancer Treatment.Research (Washington, D.C.) · 2025Article
- Regulatory influence of α-Pinene on MATN3 expression in hepatocellular carcinoma: Extending to pan-cancer analysis.PloS one · 2025Article
- The role of inhibitory immune checkpoint receptors in the pathogenesis of Alzheimer's disease.Journal of molecular medicine (Berlin, Germany) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Finding effective treatments for cancer remains a challenge. Recent studies have found that the mechanisms of tumor evasion are becoming increasingly diverse, including abnormal expression of immune checkpoint molecules on different immune cells, in particular T cells, natural killer cells, macrophages and others. In this review, we discuss the checkpoint molecules with enhanced expression on these lymphocytes and their consequences on immune effector functions. Dissecting the diverse roles of immune checkpoints in different immune cells is crucial for a full understanding of immunotherapy using checkpoint inhibitors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.